NCT02367066View on ClinicalTrials.gov

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

AR-C165395XX

Oral dose of AR-C165395XX (tablets)

OTHER

Placebo

Oral dose of placebo for AR-C165395XX (tablets)

Trial Locations (1)

Unknown

Research Site, Chula Vista

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY